🔗 Share this article

As the United States undertakes unprecedented adjustments to its vaccine schedules, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by casting doubt on Covid vaccinations throughout the pandemic and has zeroed in on alleged deaths following COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Program

Health officials were set to announce radical changes to the pediatric immunization program earlier this month, aligning the US with the Danish national calendar, it is understood – a major change that would place the US out of step with a large portion of the international standard with no evidence for public health gain. The announcement has been postponed until the next year.

Instead of the top vaccines chief, Høeg is set to address the audience at the meeting. She was recently named interim head of the FDA’s CDER, the fifth appointee to head the office this calendar year.

A Shift at the Agency

This interim role could signify a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon reevaluating long-standing immunizations at the FDA.

Høeg has frequently advocated for discontinuing some childhood vaccine recommendations in the US in order to be more in line with Denmark, a country with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

So far statements, she has persisted in emphasizing on immunizations – usually the purview of Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has no apparent track record in pharmaceutical research, approval processes or administrative roles, which has been standard for former leaders of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “understand laws and regulations and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she lacks the sort of resume that previous people who headed CBER have had.”

CDER has an vast portfolio at the FDA, the former commissioner emphasized.

“Everybody just zeroes in on the new drug program, but the generic program authorizes numerous off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and other areas, and every single one have to be managed,” she said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant leadership element to the job, which oversees more than 5,000 staff members. “It is a huge leadership role, if you perform it correctly,” she said.

Response and Disputed Initiatives

When asked about concerns about Høeg’s fitness for the role and whether this appointment signifies increased cooperation among agency officials on immunizations, a representative stated that the “concerns are based on flawed premises”.

“Her experience matches the responsibilities of her job,” the spokesperson stated, citing the time Dr. Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the agency head's controversial expedited review system, a disputed one-day drug-approval program that apparently troubled her former heads. “By what process are these therapies being chosen for this fast-track system? Who is making the decisions?” Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he said, “the FDA appears to be shifting towards laxer rules of pharmaceuticals, except for vaccines.”

Established History on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if problematic, past, critics observe. She released a research paper using unverified crowd-sourced reports to assess the frequency of myocarditis after COVID-19 vaccination. She advised the Florida top health official Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccines are more dangerous than they are.

Among her “desired changes” for the incoming government featured changing guidelines for new vaccines and discontinuing “unnecessary” vaccines, she stated following the vote on a audio program. At the agency, Høeg has reportedly floated the idea of excluding young men from obtaining COVID-19 vaccinations.

“She is an complete true believer who starts off with her preconceived notions and reverse-engineers to fit the data in a highly disingenuous, untruthful way,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Høeg became part of other dissenters, {like|